As of Friday close, Lexicon Pharmaceuticals Inc.’s (NASDAQ:LXRX) stock was down -$0.06, moving down -5.31 percent to $1.07. The average number of shares traded per day over the past five days has been 1,677,320 shares. 1 time new highs have been achieved over the past 5 days, with a -$0.3300 fall in that time frame. In the last twenty days, the average volume was 1,667,755, while in the previous 50 days, it was 1,604,270.
Since last month, LXRX stock retreated -39.20%. Shares of the company fell to $1.0650 on 09/22/23, the lowest level in the past month. A 52-week high of $3.79 was reached on 05/05/23 after having rallying from a 52-week low of $1.12. Since the beginning of this year, LXRX’s stock price has dropped by -43.98% or -$0.8400, and marked a new high 14 times. However, the stock has declined by -71.76% since its 52-week high.
LXRX stock investors should be aware that Lexicon Pharmaceuticals Inc. (LXRX) stock had its last reported insider trading activity 9 days ago on Sep 14. WADE JEFFREY L, the President and CFO of the company, purchased of 10,000 shares for $1.38 on Sep 14. It resulted in a $13,800 investment by the insider. McDermott Wendy added 6,000 shares at an average price of $1.84 on Aug 04. The insider now owns 28,478 shares following the transaction. On Jun 29, Chief Executive Officer COATS LONNEL bought 10,000 shares at $2.16 apiece. The transaction was valued at $21,600.
Valuation Metrics
The stock’s beta is 1.25. Besides these, the trailing price-to-sales (P/S) ratio of 627.10, the price-to-book (PB) ratio of 1.18.
Financial Health
In the three months ended June 29, Lexicon Pharmaceuticals Inc.’s quick ratio stood at 10.10, while its current ratio was 10.10, showing that the company is able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending June 29 was 0.53, and the total debt-to-equity ratio was 0.53. On the profitability front, the trailing twelve-month gross margin is 98.00% percent. Based on annual data, LXRX earned $0.14 million in gross profit and brought in $0.14 million in revenue.
In Lexicon Pharmaceuticals Inc.’s quarter-end financial report for June 29, it reported total debt of $98.77 million. According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. LXRX’s revenue rose 100.0% during the quarter, while net income inched up to $0.32 million. While analysts expected Lexicon Pharmaceuticals Inc. to report -$0.17 quarterly earnings, the actual figure was -$0.22 per share, beating the consensus estimate by -29.40%. During the quarter, the company generated -$43.82 million in EBITDA. The liabilities of Lexicon Pharmaceuticals Inc. were 130.36 million at the end of its most recent quarter ended June 29, and its total debt was $105.55 million. The value of shareholders’ equity is $244.93 million.
Technical Picture
This quick technical analysis looks at Lexicon Pharmaceuticals Inc.’s (LXRX) price momentum. With a historical volatility rate of 68.04%, the RSI 9-day stood at 13.64% on 22 September.
With respect to its five-day moving average, the current Lexicon Pharmaceuticals Inc. price is down by -23.57% percent or -$0.3300. At present, LXRX shares trade -38.51% below its 20-day simple moving average and -56.15% percent below its 100-day simple moving average. However, the stock is currently trading approximately -53.48% below its SMA50 and -50.46% below its SMA200.
Stochastic coefficient K was 1.76% and Stochastic coefficient D was 2.12%, while ATR was 0.0937. Given the Stochastic reading of 0.76% for the 14-day period, the RSI (14) reading has been calculated as 19.07%. As of today, the MACD Oscillator reading stands at -0.1544, while the 14-day reading stands at -0.2707.
Analyst Ratings
Jefferies launched its rating on Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX) to a Hold in a note to investors on March 07, 2023. Lexicon Pharmaceuticals Inc. (LXRX) has been rated Overweight by analysts. According to 0 brokerage firms, LXRX is a sell, and 2 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Lexicon Pharmaceuticals Inc. stock as buy, with 2 recommending it as overweight.
With a median target price of $5.00, the current consensus forecast for the stock is $1.65 – $10.00. Based on these forecasts, analysts predict Lexicon Pharmaceuticals Inc. (LXRX) will achieve an average price target of $5.55.
